Skip to main content
. 2018 May 29;9(41):26353–26369. doi: 10.18632/oncotarget.25293

Figure 4. Analysis of human CD4+ and CD8+ T cell subsets in CLL transplanted NSG spleens.

Figure 4

(A) Representative human T cell flow cytometric analysis (day 21) of spleens of human CLL transplanted NSG mice treated with carrier or LDC526 for 5 days, respectively (experimental scheme as outlined in Figure 3A). (B) CD4/CD8 ratios of residual human T cells in NSG spleens after LDC526 treatment were determined. Each data point represents the calculated mean CD4/CD8 ratio of residual T cells per individual CLL patient (day 17 analysis: n=2 patients; day 21 analysis: n=2 patients).